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The aim of the prospective study was to explore the safety and effectiveness of external beam
radiation therapy (EBRT) in three patients with biopsy proven primary pulmonary amyloidosis,
including two tracheobronchial amyloidosis patients and one primary parenchymal amyloidosis
patient. All three patients were treated to 24 Gy in 12 fractions utilizing CT simulation and 3-D
planning. All three patients had significant improvement in clinical symptoms, radiological
imaging as well as pulmonary function tests. The improvement in the clinical symptoms was
evident in 2 days. Toxicities related to EBRTwere not observed during the follow-up range from
42 to 54 months. EBRT to 24 Gy was safe and effective in the three patients with primary
pulmonary amyloidosis, and resulted in rapid relief of pulmonary symptoms.
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Primary pulmonary amyloidosis is a rare condition with poor
prognosis in some patients. Bronchoscopic intervention
with mechanical debulking by either forceps resection or
laser therapy is the essential treatment for pulmonary
amyloidosis. Although both techniques aim at maintenance
of patients’ airways, they offer only a temporary solution
while the disease usually recurs and progresses.1e3 External
beam radiation therapy (EBRT) has been recently reported
in the management of this rare condition,4e6 but it has not
been used widely. One major concern about EBRT is its.
1064 S. Ren, G. Renradiological side effects. Herein we report three cases with
primary pulmonary amyloidosis in different forms treated
with EBRT at Lishui Central Hospital prospectively since
2007. The dose, response, side effects, and complications
of EBRT in the treatment of different primary pulmonary
amyloidosis were addressed in this paper.
Methods
The project was approved by The Medical Ethics Committee
of the hospital. Three patients were consecutively diag-
nosed with primary pulmonary amyloidosis in Lishui Central
Hospital from June 2007 to May 2008 and were prospec-
tively registered in the study at the time the diagnosis was
established. The diagnosis of primary pulmonary amyloid-
osis is based on the biopsy specimens obtained by trans-
bronchial lung biopsy or percutaneous transpulmonary CT-
guided lung biopsy. Amyloid deposits were detected in all
the biopsy specimens. Histologically, the specimens con-
tained acidophilic homogeneous material which exhibited
an orange color on Congo red staining. The patients were
followed continuously to exclude any conditions that could
associate with pulmonary amyloidosis, such as systemic
amyloidosis, malignancy and connective tissue disease.
After the diagnosis was established and consent docu-
ments were obtained from the patients, EBRT was carried
out. All patients were CT simulation oriented with GE SYS-
TEC 400iCT and Software ADW1.2 and treated with 6 MV
high-energy X-ray produced by General Electric Saturn 41
Linear Accelerators. The calculated dose received by each
patient was around 24 Gy, administrated as 200 cGy per
fraction, 5 fractions a week and total 12 fractions (without
lung correction) in 21/2 weeks. Treatment boundaries
included a 1 cm margin around the primary lesions. The
patients were checked-up daily for any changes taken place
and blood routine test, including complete blood count and
differential count, performed twice a week during EBRT to
monitor the hematological toxicity of the radiotherapy. All
patients were discharged after completion of EBRT and
followed up at outpatient department or by phone calls
every 2e3 months or on the doctor’s advice.Figure 1 Chest CT of Case 1. (A) Airways were narrowed extensiv
airways was wider obviously and hyperinflation was disappeared 2Result
Case 1
Presentation
A 44-year-old female was admitted with productive cough,
dyspnea and hemoptysis for 10 days. The dyspnea became
worse at taking activities or sleeping on the left side. There
were fatigue and anorexia without fever, chest pain and
night sweat. She was excellent healthy prior to the illness
with no significant past medical history.
Physical examination
The patient was in an acute condition with slight cyanosis
and noted progressive dyspnea. Temperature 36.4 C, pulse
106/min, respirations 25/min, blood pressure 130/88 mm
Hg. The pulse oxygen saturation (SpO2) was around 90%
under nonrebreathing mask O2 supply (FiO2Z 100%) with
high oxygen flow of 5 l/min. Chest auscultation revealed
bilateral inspiratory and expiratory wheezes at upper part
of the lungs. The heart and abdomen were normal.
Investigations
All biochemical parameters and blood cells were within
normal range. Chest CT-scans revealed deformation and
narrowing of trachea and left main bronchus caused by
irregular thickness of the bronchial wall, and enlarged
subcarinal lymph nodes (Fig. 1A). All biochemical parame-
ters and blood cells were within normal range. Arterial
blood gas (ABG) (100% oxygen connecting with face mask):
pH 7.4, PaCO2 39 mm Hg, PaO2 74 mm Hg, HCO3
 24 mmol/L,
TCO2 25 mmol/L, ABE-0.1 mmol/L. SaO2 95%. On the 2nd
hospital day, pulmonary function tests (PFT) showed
moderate obstruction abnormality of FVC 3.9 L(141% pred),
FEV1 1.8 L(79% pred), FEV1/FVC 48%(59% pred), flow volume
curve revealed an inner thorax obstruction of upper airway.
After oxygenation and antibiotics therapy, the patient’s
symptoms were relieved gradually; flexible fiberoptic
bronchoscopy was performed to examine the origin of the
bleeding. Multiple protuberant nodular lesions were
observed with pebble-like surface, causing severe stenosisely and bilateral hyperinflation at pretreatment. (B) The size of
months after EBRT.
External beam radiation therapy e treating primary pulmonary amyloidosis 1065at the trachea and severe block at the openings of the left
main bronchia and hyparterial branchright. The complete
bronchial mucosa was injected and bled easily (Fig. 2A
and B). Endobronchial biopsy specimens showed abundant
submucosal amorphous pinkish material consistent with
amyloid after Congo Red staining (Fig. 3). The diagnosis of
tracheobronchial amyloidosis was established (Day 0).
Treatment
She was given colchicine and prednisone, but without
improvement. After Day 5, EBRT was initiated, 24 Gy in 12
fractions, 5 fractions a week over 18 days. On the 2nd day
of EBRT, the patient noted a significant improvement with
her dyspenea. Oxygenation therapy was stopped gradually
in the first week of EBRT.
On the 2nd day of EBRT completion, chest CT showed
obvious abatement of the irregular thickness of bronchial
wall. ABG(room air): pH 7.5, PaCO2 31 mm Hg, PaO2 85 mm
Hg, HCO3
 23 mmol/L. Pulmonary function test revealed
normal results: FVC4.0 L(146%pred), FEV1 2.9 L(124% pred),
FEV1/ FVC 73%(90%pred). Prednisone was tapped off in
6 weeks, and colchicine was stopped in 2 months. After
two months of discharge she was in a healthy status,
chest CT showed a continuous improvement (Fig. 1B).Figure 2 Case 1 Bronchoscopical findings reveal multiple pebbl
deposit at the opening of hyparterial branchright before EBRT (B), s
after EBRT (C and D).Reexaminations of bronchoscopy revealed abatement of
the lesions, smoother mucosa and less obstruction of the
orifices of bronchi gradually (Fig. 2C and D). She remained
free of symptoms and signs at follow-up of 54 months.
Case 2
Presentation
A 58-year-old man presented with a 5-years history of
recurrent fever, cough and dyspnea. Five years ago, he was
diagnosed as endobronchial amyloses by transbronchial
biopsy. He received prednisone to relieve his conditions.
After six months of steroids therapy, although his respira-
tory symptoms were relived gradually, there were hip joint
pain and dysbasia, the bone necrosis of femoral head was
diagnosed on X-ray and magnetic resonance imaging. He
suffered from recurrent cough and fever since then, and
had to be treated with antimicrobial agents against lung
infections almost every month. He was healthy prior to the
illness with no significant past medical history.
Physical examination
The patient was thin with chronically ill-appearing; there
were slight rhonchi at bilateral upper lung and basilar rales.e nodular lesions at the carina (A), and a bulkage of amyloid
ubsequent improvements were seen at the same sites 2 months
Figure 3 Bronchial biopsy indicating amyloid deposition in the bronchial wall lamina propria below the mucosal surface (Congo
red, 200 Panel A, 400 right, Panel B) B cells weakly stained (CD79a, Panel C; CD3, Panel D).
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Chest CT showed narrowed bronchial lumen diffusely, part
of them irregular. (Fig. 4A and B) and pulmonary function
tests identified severe airflow obstruction (FVC 3.43L,
85.8%pred, FEV1 1.10 L; 34.3% pred, FEV1/FVC 32.0%, 41.5%
pred).
Treatment
He received EBRT, dose and schedule as same as that in
case 1. On the 2nd day of EBRT, the patient noted his chest
tight and dyspnea relived greatly. The antibiotics were
stopped in a week. No adverse effects of both clinical signs
and laboratory data were observed during EBRT. Two
months later PFT showed improvements (FVC 3.93 L 98.6%
prediction; FEV1 1.33L 41.7% prediction; FEV1/FVC 33.9%
43.9% pred). He was in a stable condition after 46 months of
discharge; chest CT showed subsequent improvement
(Fig. 4C and D) antimicrobial agents were not needed for
treating respiratory infection anymore.
Case 3
Presentation
A 52-year-old male was admitted with a history of 4 months
of cough, short breath and chest pain. He had smoked for
about 30 years. His past history and family history were
non-contributory.
Physical examination
The patient was well built and nourished, his vital signs
were normal without abnormal findings.
Investigations
All blood cells and biochemical parameters were within
normal range. Chest CT showed a mass of 4 cm in diameterat the left lower lobe, associated with localemphysemaand
a small amount of pleural effusions (Fig. 5A). Bronchoscopy
revealed that the orifices of basal subsegment of the left
lower lobe were partly closed, suggesting the possibility of
lung cancer. Percutaneous transpulmonary CT-guided lung
biopsy showed that homosphere eosinophilous substance
deposited in the submucosa of bronchus. These deposits
were positive for Congo red staining. In this case, the form
of amyloid deposition was parenchymal pulmonary
amyloidosis was diagnosed.
Treatment
The patient underwent EBRT described above and his
symptoms of chest pain, cough and dyspnea were relieved
significantly on the 2nd day of EBRT, and then went off
gradually. He discharged in a disease free state after the
completion of EBRT. The patient was keeping healthy at 42
months of follow-up. A series of chest CT showed the size of
the mass was kept shrinking, and the pleural effusions were
disappeared completely soon after EBRT and never
recurred since then (Fig. 5B).
Pneumonitis, esophagitis, leukopenia and dermatitis
were not observed during EBRT, no any other side effects
related to radiotherapy were reported during the following
in outpatient department or by phone calls after discharge
in all patients.Discussion
Case 1 and Case 2 were both diagnosed as tracheobronchial
amyloidosis, which is the most common form of primary
pulmonary amyloidosis. Tracheobronchial amyloidosis
usually occurs in male at median age of 50’s to 60’s.1e4 It
presents almost virtually in the absence of systemic
Figure 4 Chest CT from Case 2 at presentation displayed extensive narrowing of the airways (A, B). Chest CT taken at the same
level 18 months after EBRT showed subsequent improvement (C, D).
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this condition are nonspecific but are related to the
anatomic sites involved. Thus patients with proximal
disease tend to have upper airways obstruction, while those
with distal disease have lobar collapse and recurrent
infections, such as Case 1 and Case 2 respectively. Thera-
peutic options for localized amyloidosis in respiratory
system are largely dependent upon symptoms.1e3 It is no
doubt that the conditions in Case 1 and Case 2 must be
treated. Nodular pulmonary amyloidosis like that in Case 3
is also called amyloid tumors of the lungs, and often raises
a suspicion of peripheral lung carcinoma and requires
cytological or histological examination. It usually does not
need treatment unless space-occupying effects occur, our
Case 3 was treated for his chest pain and pleural effusions,
it is the first report of nodular pulmonary amyloidosis
treated with EBRT. Not only all symptoms were significantly
relieved, but also the size of amyloid tumor at the left
lower lobe had somehow reduction soon after the
completion EBRT. The disappearance of pleural effusions
were observed soon after EBRT, and never recurred since
then, while the size of the amyloid tumor was keeping
shrinkage.
Various therapies have been utilized for the treatment
of primary pulmonary amyloidosis, either chemo-
therapeutical or non-chemotherapeutical. Chemothera-
peutic agents include melphalan, corticosteroids,colchicine, dimethyl sulfoxide (DMSO), but all of them were
less effective or no benefit at all.4e6 Non-chemotherapy
includes bronchoscopic intervention with mechanical
debulking by forceps resection or laser therapy. Although
this has been effective in relieving airway obstruction but
has the disadvantage of bleeding due to the friable nature
of the amyloid deposits. In addition, the recurrence of
lesions, and the inaccessibility of some lesions can also
limit the use of bronchoscopic intervention.1,2,4
Since 1998, successful treatment with EBRT has been
reported for tracheobronchial amyloidosis.4e6 Among them
the largest series of seven cases were reported by Neben-
Wittich.5 During the follow-up ranged from 10 to 69 months
(median, 40 months), all 7 patients had a favorable
response to treatment ranging from symptom relief to
a decrease in the frequency of pulmonary infections and
objective improvement in pulmonary function. The time to
subjective improvement ranged from 1 month to 1 year
after the completion of EBRT. One patient was improved
shortly after radiation, but the exact interval was not
given. Low toxicities of esophagitis or pneumonitis were
noted in 5/7 patients. As FEV1 was the most consistently
used parameter for follow-up, FEV1 of three patients
showed different degrees of improvements.5 Our patients
also showed symptomatic, bronchoscopic, and lung func-
tion improvement after treatment with EBRT. However we
noted the most distinctive characteristics of the instant
Figure 5 Chest CT from Case 3 showed a mass of 4 cm in diameter at the left lower lobe (arrow), associated with a small amount
of pleural effusions before EBRT (A). The mass was shrunken with the disappearance of the pleural effusions 27 months after
EBRT (B).
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significant improvement of dyspnea on the next day after
EBRT, all 3 patients also have been staying in a disease free
state during the follow-up for more than 3 years. Thus we
believe it is of great importance to explore the mechanism
of EBRT in the treatment of pulmonary amyloidosis, to
explore the efficacy and safety issues related to EBRT and
hopefully extend the use of the innovative therapy to this
rare disease, which is currently treated by routine methods
without much success.
The exact mechanisms involved in amyloid formation
and deposition are not completely understood; however
there are a number of pathogenic factors are thought to be
important. Chronic inflammation is one of the important
factors that stimulate amyloid formation.1,2,5 Chronic
inflammation, whether it is a cause or consequence of
amyloidosis, presented indeed in our patients as well as
those in literatures. There are several reports of intense
fluorodeoxyglucose (FDG) activity in pulmonary amyloid
lesions on positron emission tomography (PET) scan, indi-
cating chronic inflammation is involved in amyloid
lesions.7,8
Radiotherapy has been used successfully in a series of
benign diseases, doses given for the different indications
range from those used in cancer therapy to less than 1% of
those doses, very different mechanism will be involved in
the therapeutic action of radiotherapy on the different
benign pathological processes, including anti-inflammatory
radiation effects.8e10 Ro¨del et al.9 confirmed that after
irradiated 2 Gy dose the expression of inducible nitric oxide
synthase (iNOS), a mediator of acute phase of inflammation
was decreased, while the expression of heme oxygenase-1
(HO-1), a mediator of chronic phase of inflammation was
increased in an air pouch model in mice. iNOS was raised in
several conditions, including asthma and leads cell death
and tissue damage. HO-1 confers cytoprotection against
oxidative stress.
Arenas et al.11 found that low-dose radiotherapy (LD-RT)
has a significant anti-inflammatory effect, inhibiting
leukocyte recruitment in mice when pretreated with three
different radiation doses 0.1, 0.3 and 0.6 Gy. All of the
three doses tested significantly reduced the number of
adherent leukocytes. Interestingly, the highest inhibition
was observed for the medium dose 0.3 Gy. In another study,dose-dependent modulation of the NO pathway was
observed with significant inhibition by the low radiation
doses used in anti-inflammatory radiotherapy but with
super-stimulation by the high radiation doses used in cancer
therapy, although in stimulated macrophages, metabolic
activity, proliferation and reproductive integrity were not
affected by radiation doses up to 10 Gy since they are
apparently irreversible post-mitotic cells. In another
study,12 the authors found the number of adherent leuko-
cytes was significantly reduced 5, 24 and 48 h, but not 72 h
after irradiation in LPS-challenged mice. Rolling leukocytes
were significantly decreased at all time points analyzed.
Plasma transforming growth factor beta 1(TGF-b1) levels
were increased 5 and 24 h after irradiation. Increased
intestinal production during this period was corroborated
by in vitro culture experiments. LD-RT has a sustained
inhibitory effect on leukocyte recruitment for 48 h. The
empirically based anti-inflammatory radiotherapy of benign
diseases appears to act through specific modulation of
different pathways of inflammatory reactions such as the
nitric oxide pathway in stimulated macrophages. Other
possibilities involved might be that the radiation therapy
has an effect on local plasma cells, which cause light chain
deposition, forming amyloid deposits in patients with
tracheobronchial amyloidosis.5,6
We hypothesized that at the early stage of EBRT it is the
anti-inflammatory radiation effects that bring the reduc-
tion of the release of inflammatory mediators, including
those could stimulates bronchial contraction, eventually
brought relief of dyspnea in the patients, all three patients
and possible one of Neben-Wittich’s, after the first dose of
EBRT. At the later stage of EBRT, radiation causes inhibition
local plasma cells thus bringing further therapeutic effects
for all patients. However, an exact mechanism of EBRT in
primary pulmonary amyloidosis should be carried out in
further study.
Different from the literature, according to Neben-
Wittich and his colleagues’ report,5 the incidence of
acute esophagitis was relatively high with EBRT (5/7
patients), radiotherapy induced esophagitis did not occur in
our group, There are some recognized risk factors for acute
esophagitis with EBRT, such as concurrent chemo-
radiotherapy and high dosimetric predictive factors (the
surface area of the esophagus receiving 55 Gy or more and
External beam radiation therapy e treating primary pulmonary amyloidosis 1069the doseevolume receiving 60 Gy or more).13,14 But it was
not the case in our study. The difference of esophagitis
incidences might contribute to the ethnic diversity or
different eating habits.14
Conclusion
In summary, EBRT is effective and safe approach to
managements of primary pulmonary amyloidosis. The
response to EBRT in primary pulmonary amyloidosis
patients is fast, consistent and long lasting. With compre-
hensive understanding of this rare disease, EBRT could
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